Premium
Regulation of fibroblast growth factor 23 ( FGF 23) in health and disease
Author(s) -
Bär Ludmilla,
Stournaras Christos,
Lang Florian,
Föller Michael
Publication year - 2019
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.13494
Subject(s) - fibroblast growth factor 23 , fibroblast growth factor , paracrine signalling , klotho , fgf21 , endocrinology , medicine , receptor , fibroblast , fgf19 , endocrine system , microbiology and biotechnology , biology , hormone , kidney , parathyroid hormone , biochemistry , calcium , in vitro
Fibroblast growth factor 23 ( FGF 23) is mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF 23 can exert several endocrine functions, such as inhibiting renal phosphate reabsorption and 1,25‐dihydroxyvitamin D3 production. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. Klotho and Fgf23 deficiencies result in pathologies otherwise encountered in age‐associated diseases, mainly as a result of hyperphosphataemia‐dependent calcification. FGF 23 levels are also perturbed in the plasma of patients with several disorders, including kidney or cardiovascular diseases. Here, we review mechanisms controlling FGF 23 production and discuss how FGF 23 regulation is perturbed in disease.